Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Hsu

Physical Medicine & Rehabilitation Reno, NV Medical Doctor

NPI 1881910255 CMS profile 312968

9990 Double R Blvd Ste 200, Reno, NV 89521

Open in the dashboard

General payments

$7,218

263 records reported · program years 2019–2025

Research payments

$16

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Hsu of Reno, NV is reported in the CMS Open Payments database as having received $7,218 across 263 general payments and $16 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $605 18
2024 General $679 22
2023 General $509 18
2022 General $982 58
2021 General $1,050 56
2021 Research $16 1
2020 General $835 39
2019 General $2,559 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Hsu
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Andrew Hsu were reported at $605. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Andrew Hsu Physical Medicine & Rehabilitation median Middle half National median
2019 $2,559 $133 $45–$390 $163
2020 $835 $88 $29–$272 $114
2021 $1,050 $116 $33–$360 $132
2022 $982 $123 $40–$378 $149
2023 $509 $131 $43–$396 $160
2024 $679 $141 $45–$409 $164
2025 $605 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $2,267 115 payments
  2. Medtronic USA, Inc. $1,817 22 payments
  3. Nalu Medical, Inc. $703 27 payments
  4. Abbott Laboratories $285 14 payments
  5. Amgen Inc. $284 9 payments
  6. AbbVie, Inc. $283 19 payments
  7. SPR Therapeutics, Inc $207 2 payments
  8. Collegium Pharmaceutical, Inc. $137 7 payments
  9. Globus Medical, Inc. $136 6 payments
  10. Stimwave Technologies Incorporated $122 2 payments
  11. Other $977 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,067 258 payments
  2. Travel and Lodging $1,151 5 payments
Products named General payments · program years 2019–2025
  1. Omnia $1,047 61 payments
  2. INTELLIS $846 7 payments
  3. Nalu Neurostimulation System $703 27 payments
  4. Senza Spinal Cord Stimulation System $676 37 payments
  5. Senza $538 16 payments
  6. ADAPTIVESTIM $374 1 payment
  7. AIMOVIG $284 9 payments
  8. SYNCHROMED $256 4 payments
  9. RESTORE $236 7 payments
  10. QULIPTA $220 15 payments
  11. Other $2,373 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $16 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

4,186

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$80,903

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

23.8%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 616 $12,620
Hysingla Er Hydrocodone Bitartrate Brand 12 $8,329
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 244 $7,546
Gabapentin Generic 413 $6,849
Methocarbamol Generic 414 $5,745
Savella Milnacipran Hcl Brand 12 $5,686
Oxycodone Hcl Generic 286 $5,512
Oxycontin Oxycodone Hcl Brand 11 $3,648
Pregabalin Generic 200 $3,195
Diclofenac Sodium Generic 141 $2,834

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 114 billing codes

Paid by Medicare

$452,136

Of which drugs: $5,301

Medicare patients

783

Average age 73

Services billed

11,174

439 women, 344 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 28%
Ischemic heart disease 25%
Depression 24%
Chronic kidney disease 19%
Osteoporosis 17%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 191 1,818 $1,355
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 176 4,472 $387
Injection, ropivacaine hydrochloride, 1 mg J2795 Office 11 43 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $21
$21 — —
NURTEC ODT
  • PFIZER INC. $8
$8 — —
ZAVZPRET
  • PFIZER INC. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record